Reports Q4 revenue $166.0M, consensus $160.35M. “In 2025, our team executed with discipline through a challenging environment while continuing to strengthen the fundamentals of the business,” said Serge Saxonov, Co-founder and CEO of 10x Genomics (TXG). “As we look to 2026, I am excited by the expanding impact of our platforms, driven by new product innovations and strategic partnerships. We are well positioned to execute across multiple growth vectors in the business, especially AI-driven demand, translational research and emerging clinical opportunities.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Cathie Wood Sells Biotech Stocks, Bets Big on Tempus AI and WeRide
- Cathie Wood Loads Up on Broadcom and Crypto Stocks, Trims Meta by $8M Ahead of Q4. Here’s Why
- Cathie Wood Doubles Down on High-Potential Biotech Plays
- 10x Genomics: Solid Q4 Rebound but Sustainability Questions Justify Maintaining Hold
- 10x Genomics announces collaboration with Dana-Farber Cancer Institute